Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we present interim analyses from the KEYNOTE-204 study evaluating pembrolizumab versus brentuximab vedotin for relapsed or refractory class...
Saved in:
| Published in | The lancet oncology Vol. 22; no. 4; pp. 512 - 524 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.04.2021
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we present interim analyses from the KEYNOTE-204 study evaluating pembrolizumab versus brentuximab vedotin for relapsed or refractory classical Hodgkin lymphoma.
In this randomised, open-label, phase 3 study, patients aged 18 years or older with relapsed or refractory classical Hodgkin lymphoma with measurable disease and an Eastern Cooperative Oncology Group performance status of 0 or 1 who were ineligible for or had relapsed after autologous haematopoietic stem-cell transplantation (HSCT) were enrolled at 78 hospitals and cancer centres in 20 countries and territories. Patients were randomly assigned (1:1) with an interactive voice response system to pembrolizumab 200 mg intravenously every 3 weeks or brentuximab vedotin 1·8 mg/kg intravenously every 3 weeks. Randomisation was stratified by previous autologous HSCT and status after front-line therapy. Results from the second interim analysis are presented here, with a database cutoff of Jan 16, 2020. The dual primary endpoints assessed in the intention-to-treat population were progression-free survival as assessed by blinded independent central review, and overall survival (not analysed at this interim analysis). Safety was assessed in all patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, NCT02684292. Recruitment for this trial is closed.
Between July 8, 2016, and July 13, 2018, 151 patients were randomly assigned to pembrolizumab and 153 to brentuximab vedotin. After a median time from randomisation to data cutoff of 25·7 months (IQR 23·4–33·0), median progression-free survival was 13·2 months (95% CI 10·9–19·4) for pembrolizumab versus 8·3 months (5·7–8·8) for brentuximab vedotin (hazard ratio 0·65 [95% CI 0·48–0·88]; p=0·0027). The most common grade 3–5 treatment-related adverse events were pneumonitis (six [4%] of 148 patients in the pembrolizumab group vs one [1%] of 152 patients in the brentuximab vedotin group), neutropenia (three [2%] vs 11 [7%]), decreased neutrophil count (one [1%] vs seven [5%]), and peripheral neuropathy (one [1%] vs five [3%]). Serious treatment-related adverse events occurred in 24 (16%) of 148 patients receiving pembrolizumab and 16 (11%) of 152 patients receiving brentuximab vedotin. One treatment-related death due to pneumonia occurred in the pembrolizumab group.
Pembrolizumab showed statistically significant and clinically meaningful improvement in progression-free survival compared with brentuximab vedotin, with safety consistent with previous reports. These data support pembrolizumab as the preferred treatment option for patients with relapsed or refractory classical Hodgkin lymphoma who have relapsed post-autologous HSCT or are ineligible for autologous HSCT.
Merck Sharp & Dohme Corp (a subsidiary of Merck & Co, Inc, Kenilworth, NJ, USA).
For the Portuguese translation of the Article see Supplementary Materials section. |
|---|---|
| AbstractList | SummaryBackgroundPD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we present interim analyses from the KEYNOTE-204 study evaluating pembrolizumab versus brentuximab vedotin for relapsed or refractory classical Hodgkin lymphoma. MethodsIn this randomised, open-label, phase 3 study, patients aged 18 years or older with relapsed or refractory classical Hodgkin lymphoma with measurable disease and an Eastern Cooperative Oncology Group performance status of 0 or 1 who were ineligible for or had relapsed after autologous haematopoietic stem-cell transplantation (HSCT) were enrolled at 78 hospitals and cancer centres in 20 countries and territories. Patients were randomly assigned (1:1) with an interactive voice response system to pembrolizumab 200 mg intravenously every 3 weeks or brentuximab vedotin 1·8 mg/kg intravenously every 3 weeks. Randomisation was stratified by previous autologous HSCT and status after front-line therapy. Results from the second interim analysis are presented here, with a database cutoff of Jan 16, 2020. The dual primary endpoints assessed in the intention-to-treat population were progression-free survival as assessed by blinded independent central review, and overall survival (not analysed at this interim analysis). Safety was assessed in all patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, NCT02684292. Recruitment for this trial is closed. FindingsBetween July 8, 2016, and July 13, 2018, 151 patients were randomly assigned to pembrolizumab and 153 to brentuximab vedotin. After a median time from randomisation to data cutoff of 25·7 months (IQR 23·4–33·0), median progression-free survival was 13·2 months (95% CI 10·9–19·4) for pembrolizumab versus 8·3 months (5·7–8·8) for brentuximab vedotin (hazard ratio 0·65 [95% CI 0·48–0·88]; p=0·0027). The most common grade 3–5 treatment-related adverse events were pneumonitis (six [4%] of 148 patients in the pembrolizumab group vs one [1%] of 152 patients in the brentuximab vedotin group), neutropenia (three [2%] vs 11 [7%]), decreased neutrophil count (one [1%] vs seven [5%]), and peripheral neuropathy (one [1%] vs five [3%]). Serious treatment-related adverse events occurred in 24 (16%) of 148 patients receiving pembrolizumab and 16 (11%) of 152 patients receiving brentuximab vedotin. One treatment-related death due to pneumonia occurred in the pembrolizumab group. InterpretationPembrolizumab showed statistically significant and clinically meaningful improvement in progression-free survival compared with brentuximab vedotin, with safety consistent with previous reports. These data support pembrolizumab as the preferred treatment option for patients with relapsed or refractory classical Hodgkin lymphoma who have relapsed post-autologous HSCT or are ineligible for autologous HSCT. FundingMerck Sharp & Dohme Corp (a subsidiary of Merck & Co, Inc, Kenilworth, NJ, USA). PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we present interim analyses from the KEYNOTE-204 study evaluating pembrolizumab versus brentuximab vedotin for relapsed or refractory classical Hodgkin lymphoma.BACKGROUNDPD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we present interim analyses from the KEYNOTE-204 study evaluating pembrolizumab versus brentuximab vedotin for relapsed or refractory classical Hodgkin lymphoma.In this randomised, open-label, phase 3 study, patients aged 18 years or older with relapsed or refractory classical Hodgkin lymphoma with measurable disease and an Eastern Cooperative Oncology Group performance status of 0 or 1 who were ineligible for or had relapsed after autologous haematopoietic stem-cell transplantation (HSCT) were enrolled at 78 hospitals and cancer centres in 20 countries and territories. Patients were randomly assigned (1:1) with an interactive voice response system to pembrolizumab 200 mg intravenously every 3 weeks or brentuximab vedotin 1·8 mg/kg intravenously every 3 weeks. Randomisation was stratified by previous autologous HSCT and status after front-line therapy. Results from the second interim analysis are presented here, with a database cutoff of Jan 16, 2020. The dual primary endpoints assessed in the intention-to-treat population were progression-free survival as assessed by blinded independent central review, and overall survival (not analysed at this interim analysis). Safety was assessed in all patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, NCT02684292. Recruitment for this trial is closed.METHODSIn this randomised, open-label, phase 3 study, patients aged 18 years or older with relapsed or refractory classical Hodgkin lymphoma with measurable disease and an Eastern Cooperative Oncology Group performance status of 0 or 1 who were ineligible for or had relapsed after autologous haematopoietic stem-cell transplantation (HSCT) were enrolled at 78 hospitals and cancer centres in 20 countries and territories. Patients were randomly assigned (1:1) with an interactive voice response system to pembrolizumab 200 mg intravenously every 3 weeks or brentuximab vedotin 1·8 mg/kg intravenously every 3 weeks. Randomisation was stratified by previous autologous HSCT and status after front-line therapy. Results from the second interim analysis are presented here, with a database cutoff of Jan 16, 2020. The dual primary endpoints assessed in the intention-to-treat population were progression-free survival as assessed by blinded independent central review, and overall survival (not analysed at this interim analysis). Safety was assessed in all patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, NCT02684292. Recruitment for this trial is closed.Between July 8, 2016, and July 13, 2018, 151 patients were randomly assigned to pembrolizumab and 153 to brentuximab vedotin. After a median time from randomisation to data cutoff of 25·7 months (IQR 23·4-33·0), median progression-free survival was 13·2 months (95% CI 10·9-19·4) for pembrolizumab versus 8·3 months (5·7-8·8) for brentuximab vedotin (hazard ratio 0·65 [95% CI 0·48-0·88]; p=0·0027). The most common grade 3-5 treatment-related adverse events were pneumonitis (six [4%] of 148 patients in the pembrolizumab group vs one [1%] of 152 patients in the brentuximab vedotin group), neutropenia (three [2%] vs 11 [7%]), decreased neutrophil count (one [1%] vs seven [5%]), and peripheral neuropathy (one [1%] vs five [3%]). Serious treatment-related adverse events occurred in 24 (16%) of 148 patients receiving pembrolizumab and 16 (11%) of 152 patients receiving brentuximab vedotin. One treatment-related death due to pneumonia occurred in the pembrolizumab group.FINDINGSBetween July 8, 2016, and July 13, 2018, 151 patients were randomly assigned to pembrolizumab and 153 to brentuximab vedotin. After a median time from randomisation to data cutoff of 25·7 months (IQR 23·4-33·0), median progression-free survival was 13·2 months (95% CI 10·9-19·4) for pembrolizumab versus 8·3 months (5·7-8·8) for brentuximab vedotin (hazard ratio 0·65 [95% CI 0·48-0·88]; p=0·0027). The most common grade 3-5 treatment-related adverse events were pneumonitis (six [4%] of 148 patients in the pembrolizumab group vs one [1%] of 152 patients in the brentuximab vedotin group), neutropenia (three [2%] vs 11 [7%]), decreased neutrophil count (one [1%] vs seven [5%]), and peripheral neuropathy (one [1%] vs five [3%]). Serious treatment-related adverse events occurred in 24 (16%) of 148 patients receiving pembrolizumab and 16 (11%) of 152 patients receiving brentuximab vedotin. One treatment-related death due to pneumonia occurred in the pembrolizumab group.Pembrolizumab showed statistically significant and clinically meaningful improvement in progression-free survival compared with brentuximab vedotin, with safety consistent with previous reports. These data support pembrolizumab as the preferred treatment option for patients with relapsed or refractory classical Hodgkin lymphoma who have relapsed post-autologous HSCT or are ineligible for autologous HSCT.INTERPRETATIONPembrolizumab showed statistically significant and clinically meaningful improvement in progression-free survival compared with brentuximab vedotin, with safety consistent with previous reports. These data support pembrolizumab as the preferred treatment option for patients with relapsed or refractory classical Hodgkin lymphoma who have relapsed post-autologous HSCT or are ineligible for autologous HSCT.Merck Sharp & Dohme Corp (a subsidiary of Merck & Co, Inc, Kenilworth, NJ, USA).FUNDINGMerck Sharp & Dohme Corp (a subsidiary of Merck & Co, Inc, Kenilworth, NJ, USA). Summary Background PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we present interim analyses from the KEYNOTE-204 study evaluating pembrolizumab versus brentuximab vedotin for relapsed or refractory classical Hodgkin lymphoma. Methods In this randomised, open-label, phase 3 study, patients aged 18 years or older with relapsed or refractory classical Hodgkin lymphoma with measurable disease and an Eastern Cooperative Oncology Group performance status of 0 or 1 who were ineligible for or had relapsed after autologous haematopoietic stem-cell transplantation (HSCT) were enrolled at 78 hospitals and cancer centres in 20 countries and territories. Patients were randomly assigned (1:1) with an interactive voice response system to pembrolizumab 200 mg intravenously every 3 weeks or brentuximab vedotin 1·8 mg/kg intravenously every 3 weeks. Randomisation was stratified by previous autologous HSCT and status after front-line therapy. Results from the second interim analysis are presented here, with a database cutoff of Jan 16, 2020. The dual primary endpoints assessed in the intention-to-treat population were progression-free survival as assessed by blinded independent central review, and overall survival (not analysed at this interim analysis). Safety was assessed in all patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, NCT02684292. Recruitment for this trial is closed. Findings Between July 8, 2016, and July 13, 2018, 151 patients were randomly assigned to pembrolizumab and 153 to brentuximab vedotin. After a median time from randomisation to data cutoff of 25·7 months (IQR 23·4–33·0), median progression-free survival was 13·2 months (95% CI 10·9–19·4) for pembrolizumab versus 8·3 months (5·7–8·8) for brentuximab vedotin (hazard ratio 0·65 [95% CI 0·48–0·88]; p=0·0027). The most common grade 3–5 treatment-related adverse events were pneumonitis (six [4%] of 148 patients in the pembrolizumab group vs one [1%] of 152 patients in the brentuximab vedotin group), neutropenia (three [2%] vs 11 [7%]), decreased neutrophil count (one [1%] vs seven [5%]), and peripheral neuropathy (one [1%] vs five [3%]). Serious treatment-related adverse events occurred in 24 (16%) of 148 patients receiving pembrolizumab and 16 (11%) of 152 patients receiving brentuximab vedotin. One treatment-related death due to pneumonia occurred in the pembrolizumab group. Interpretation Pembrolizumab showed statistically significant and clinically meaningful improvement in progression-free survival compared with brentuximab vedotin, with safety consistent with previous reports. These data support pembrolizumab as the preferred treatment option for patients with relapsed or refractory classical Hodgkin lymphoma who have relapsed post-autologous HSCT or are ineligible for autologous HSCT. Funding Merck Sharp & Dohme Corp (a subsidiary of Merck & Co, Inc, Kenilworth, NJ, USA). PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we present interim analyses from the KEYNOTE-204 study evaluating pembrolizumab versus brentuximab vedotin for relapsed or refractory classical Hodgkin lymphoma. In this randomised, open-label, phase 3 study, patients aged 18 years or older with relapsed or refractory classical Hodgkin lymphoma with measurable disease and an Eastern Cooperative Oncology Group performance status of 0 or 1 who were ineligible for or had relapsed after autologous haematopoietic stem-cell transplantation (HSCT) were enrolled at 78 hospitals and cancer centres in 20 countries and territories. Patients were randomly assigned (1:1) with an interactive voice response system to pembrolizumab 200 mg intravenously every 3 weeks or brentuximab vedotin 1·8 mg/kg intravenously every 3 weeks. Randomisation was stratified by previous autologous HSCT and status after front-line therapy. Results from the second interim analysis are presented here, with a database cutoff of Jan 16, 2020. The dual primary endpoints assessed in the intention-to-treat population were progression-free survival as assessed by blinded independent central review, and overall survival (not analysed at this interim analysis). Safety was assessed in all patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, NCT02684292. Recruitment for this trial is closed. Between July 8, 2016, and July 13, 2018, 151 patients were randomly assigned to pembrolizumab and 153 to brentuximab vedotin. After a median time from randomisation to data cutoff of 25·7 months (IQR 23·4–33·0), median progression-free survival was 13·2 months (95% CI 10·9–19·4) for pembrolizumab versus 8·3 months (5·7–8·8) for brentuximab vedotin (hazard ratio 0·65 [95% CI 0·48–0·88]; p=0·0027). The most common grade 3–5 treatment-related adverse events were pneumonitis (six [4%] of 148 patients in the pembrolizumab group vs one [1%] of 152 patients in the brentuximab vedotin group), neutropenia (three [2%] vs 11 [7%]), decreased neutrophil count (one [1%] vs seven [5%]), and peripheral neuropathy (one [1%] vs five [3%]). Serious treatment-related adverse events occurred in 24 (16%) of 148 patients receiving pembrolizumab and 16 (11%) of 152 patients receiving brentuximab vedotin. One treatment-related death due to pneumonia occurred in the pembrolizumab group. Pembrolizumab showed statistically significant and clinically meaningful improvement in progression-free survival compared with brentuximab vedotin, with safety consistent with previous reports. These data support pembrolizumab as the preferred treatment option for patients with relapsed or refractory classical Hodgkin lymphoma who have relapsed post-autologous HSCT or are ineligible for autologous HSCT. Merck Sharp & Dohme Corp (a subsidiary of Merck & Co, Inc, Kenilworth, NJ, USA). For the Portuguese translation of the Article see Supplementary Materials section. PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we present interim analyses from the KEYNOTE-204 study evaluating pembrolizumab versus brentuximab vedotin for relapsed or refractory classical Hodgkin lymphoma. In this randomised, open-label, phase 3 study, patients aged 18 years or older with relapsed or refractory classical Hodgkin lymphoma with measurable disease and an Eastern Cooperative Oncology Group performance status of 0 or 1 who were ineligible for or had relapsed after autologous haematopoietic stem-cell transplantation (HSCT) were enrolled at 78 hospitals and cancer centres in 20 countries and territories. Patients were randomly assigned (1:1) with an interactive voice response system to pembrolizumab 200 mg intravenously every 3 weeks or brentuximab vedotin 1·8 mg/kg intravenously every 3 weeks. Randomisation was stratified by previous autologous HSCT and status after front-line therapy. Results from the second interim analysis are presented here, with a database cutoff of Jan 16, 2020. The dual primary endpoints assessed in the intention-to-treat population were progression-free survival as assessed by blinded independent central review, and overall survival (not analysed at this interim analysis). Safety was assessed in all patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, NCT02684292. Recruitment for this trial is closed. Between July 8, 2016, and July 13, 2018, 151 patients were randomly assigned to pembrolizumab and 153 to brentuximab vedotin. After a median time from randomisation to data cutoff of 25·7 months (IQR 23·4-33·0), median progression-free survival was 13·2 months (95% CI 10·9-19·4) for pembrolizumab versus 8·3 months (5·7-8·8) for brentuximab vedotin (hazard ratio 0·65 [95% CI 0·48-0·88]; p=0·0027). The most common grade 3-5 treatment-related adverse events were pneumonitis (six [4%] of 148 patients in the pembrolizumab group vs one [1%] of 152 patients in the brentuximab vedotin group), neutropenia (three [2%] vs 11 [7%]), decreased neutrophil count (one [1%] vs seven [5%]), and peripheral neuropathy (one [1%] vs five [3%]). Serious treatment-related adverse events occurred in 24 (16%) of 148 patients receiving pembrolizumab and 16 (11%) of 152 patients receiving brentuximab vedotin. One treatment-related death due to pneumonia occurred in the pembrolizumab group. Pembrolizumab showed statistically significant and clinically meaningful improvement in progression-free survival compared with brentuximab vedotin, with safety consistent with previous reports. These data support pembrolizumab as the preferred treatment option for patients with relapsed or refractory classical Hodgkin lymphoma who have relapsed post-autologous HSCT or are ineligible for autologous HSCT. Merck Sharp & Dohme Corp (a subsidiary of Merck & Co, Inc, Kenilworth, NJ, USA). |
| Author | Zhu, Ying Sekiguchi, Naohiro Ramchandren, Radhakrishnan Goncalves, Iara McDonald, Andrew Gasiorowski, Robin Santoro, Armando Paszkiewicz-Kozik, Ewa Fogliatto, Laura Maria de Oliveira, Jose S R Kuruvilla, John Buccheri, Valeria Perini, Guilherme F Zinzani, Pier Luigi Ozcan, Muhit Johnson, Nathalie A Komarnicki, Mieczyslaw Nahar, Akash Marinello, Patricia Kriachok, Iryna Dickinson, Michael Goldschmidt, Neta |
| Author_xml | – sequence: 1 givenname: John surname: Kuruvilla fullname: Kuruvilla, John email: john.kuruvilla@uhn.ca organization: Princess Margaret Cancer Centre, Toronto, ON, Canada – sequence: 2 givenname: Radhakrishnan surname: Ramchandren fullname: Ramchandren, Radhakrishnan organization: Department of Medicine, University of Tennessee, Knoxville, TN, USA – sequence: 3 givenname: Armando surname: Santoro fullname: Santoro, Armando organization: IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy – sequence: 4 givenname: Ewa surname: Paszkiewicz-Kozik fullname: Paszkiewicz-Kozik, Ewa organization: Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland – sequence: 5 givenname: Robin surname: Gasiorowski fullname: Gasiorowski, Robin organization: Concord Repatriation General Hospital, University of Sydney, Sydney, NSW, Australia – sequence: 6 givenname: Nathalie A surname: Johnson fullname: Johnson, Nathalie A organization: Jewish General Hospital Montreal, Montreal, QC, Canada – sequence: 7 givenname: Laura Maria surname: Fogliatto fullname: Fogliatto, Laura Maria organization: Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil – sequence: 8 givenname: Iara surname: Goncalves fullname: Goncalves, Iara organization: Fundação Pio XII—Hospital de Câncer de Barretos, São Paulo, Brazil – sequence: 9 givenname: Jose S R surname: de Oliveira fullname: de Oliveira, Jose S R organization: Casa de Saude Santa Marcelina, São Paulo, Brazil – sequence: 10 givenname: Valeria surname: Buccheri fullname: Buccheri, Valeria organization: Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil – sequence: 11 givenname: Guilherme F surname: Perini fullname: Perini, Guilherme F organization: Hospital Israelita Albert Einstein, São Paulo, Brazil – sequence: 12 givenname: Neta surname: Goldschmidt fullname: Goldschmidt, Neta organization: Hadassah Medical Center, Jerusalem, Israel – sequence: 13 givenname: Iryna surname: Kriachok fullname: Kriachok, Iryna organization: National Cancer Institute, Kiev, Ukraine – sequence: 14 givenname: Michael surname: Dickinson fullname: Dickinson, Michael organization: Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia – sequence: 15 givenname: Mieczyslaw surname: Komarnicki fullname: Komarnicki, Mieczyslaw organization: Szpital Kliniczny im Przemienienia, Poznań, Poland – sequence: 16 givenname: Andrew surname: McDonald fullname: McDonald, Andrew organization: Pretoria East Hospital, Pretoria, South Africa – sequence: 17 givenname: Muhit surname: Ozcan fullname: Ozcan, Muhit organization: Ankara University School of Medicine, Ankara, Turkey – sequence: 18 givenname: Naohiro surname: Sekiguchi fullname: Sekiguchi, Naohiro organization: Department of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan – sequence: 19 givenname: Ying surname: Zhu fullname: Zhu, Ying organization: Merck & Co, Kenilworth, NJ, USA – sequence: 20 givenname: Akash surname: Nahar fullname: Nahar, Akash organization: Merck & Co, Kenilworth, NJ, USA – sequence: 21 givenname: Patricia surname: Marinello fullname: Marinello, Patricia organization: Merck & Co, Kenilworth, NJ, USA – sequence: 22 givenname: Pier Luigi surname: Zinzani fullname: Zinzani, Pier Luigi organization: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33721562$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkm9r1TAUxotM3B_9CErAN3dwq0na3vYqKjKuThxOcMJ8FfLn1GVLm5qkw_rJ_Him7dyLCzJLoIfwO09Onif7yU5rW0iSxwQ_I5isnn8heYlTivNiQckhjl-Rnt9L9uJ2nhZ5Ve1M9YzsJvveX2JMSoKLB8lulpWUFCu6l_z-DI1w1uhffcMFugbne4-Egzb0P_W8pWzQLYrLgeGdB4Wsi3XtuAzWDUga7r2W3KBjq75fRdAMTXdhG44WHzffPp2ebcYpDl8gPsoEcLqJJTeD1x7ZGnHU9CZoGQ91sESOt8o2Oh60RLaDNjVcgFmi7oJ7QBnyoVfDw-R-zY2HRzf_g-Tru83Z0XF6cvr-w9Hbk1TmpAypJDkHXpNMKioyWle4khLnar2iipfrtSBiLRRVShEhsqyuQNK6FqLOcA7R1OwgWcy6nbM_evCBxckkGMNbsL1ntMCkytdVnkX06RZ6aXsX7zlRq3KMYxWpJzdULxpQrItucDewv5lEoJgB6az30edbhGA2Zs-m7NkYLKOETdmz89j3cqtP6sCDttFVrs2d3W_mbohmXmtwzEsNrQSlHcjAlNV3KrzeUpBGt-O7uIIB_K0XhHnK8CwyalAyKYwCr_4t8B8D_AGJvfLN |
| CitedBy_id | crossref_primary_10_1016_j_ctrv_2023_102647 crossref_primary_10_1182_bloodadvances_2023012145 crossref_primary_10_1016_j_tranon_2023_101851 crossref_primary_10_1016_j_clml_2021_07_006 crossref_primary_10_3389_fonc_2024_1381250 crossref_primary_10_2174_1574892818666230117151757 crossref_primary_10_3390_diagnostics14030336 crossref_primary_10_1080_10428194_2023_2193854 crossref_primary_10_1002_ajh_27459 crossref_primary_10_1016_j_canlet_2025_217616 crossref_primary_10_1002_hem3_150 crossref_primary_10_3390_cancers14071710 crossref_primary_10_1016_j_ccell_2022_12_005 crossref_primary_10_1182_hematology_2024000574 crossref_primary_10_3390_cancers15102751 crossref_primary_10_1002_jha2_629 crossref_primary_10_7759_cureus_43069 crossref_primary_10_3389_fonc_2022_925236 crossref_primary_10_3390_vaccines11121843 crossref_primary_10_1002_cai2_97 crossref_primary_10_1136_jitc_2022_005128 crossref_primary_10_3389_fonc_2024_1323914 crossref_primary_10_1016_j_beha_2023_101514 crossref_primary_10_3390_jcm11061701 crossref_primary_10_1007_s00761_022_01172_1 crossref_primary_10_3390_cancers14143526 crossref_primary_10_18632_oncotarget_28541 crossref_primary_10_3389_fimmu_2021_792691 crossref_primary_10_3390_molecules28186438 crossref_primary_10_1016_j_semradonc_2024_11_002 crossref_primary_10_1080_17474086_2021_1962278 crossref_primary_10_1182_hem_V20_4_202345 crossref_primary_10_21320_2500_2139_2022_15_1_42_53 crossref_primary_10_1182_bloodadvances_2021004970 crossref_primary_10_1016_S1470_2045_21_00290_4 crossref_primary_10_3390_ijms241210095 crossref_primary_10_3390_cancers14205022 crossref_primary_10_3390_cancers15051515 crossref_primary_10_3390_cancers15184509 crossref_primary_10_3390_cells10051152 crossref_primary_10_1001_jamaoncol_2022_7975 crossref_primary_10_1182_hematology_2021000311 crossref_primary_10_1016_j_ejca_2024_115145 crossref_primary_10_1182_blood_2023020244 crossref_primary_10_3389_fcell_2022_965803 crossref_primary_10_1200_OP_24_00277 crossref_primary_10_1016_j_leukres_2024_107633 crossref_primary_10_1080_10428194_2024_2397072 crossref_primary_10_1182_bloodadvances_2024015487 crossref_primary_10_1007_s11523_023_00983_5 crossref_primary_10_1002_pbc_29390 crossref_primary_10_3389_fimmu_2021_803410 crossref_primary_10_3390_life11111277 crossref_primary_10_1097_HS9_0000000000000869 crossref_primary_10_3390_cancers15205060 crossref_primary_10_1016_j_lrr_2022_100319 crossref_primary_10_3389_fpubh_2021_777199 crossref_primary_10_26508_lsa_202301999 crossref_primary_10_1186_s13045_024_01634_6 crossref_primary_10_1016_j_cpt_2022_11_003 crossref_primary_10_1038_s41409_021_01427_2 crossref_primary_10_3390_cancers14122936 crossref_primary_10_3390_ijms241713187 crossref_primary_10_1136_jitc_2024_010116 crossref_primary_10_1007_s10637_024_01499_z crossref_primary_10_1038_s41573_023_00709_2 crossref_primary_10_3389_fonc_2024_1392653 crossref_primary_10_3389_fimmu_2023_1171981 crossref_primary_10_1182_bloodadvances_2023011205 crossref_primary_10_3389_fimmu_2023_1088874 crossref_primary_10_1080_16078454_2023_2181749 crossref_primary_10_1200_EDBK_433502 crossref_primary_10_1111_ejh_13915 crossref_primary_10_3390_cancers13236125 crossref_primary_10_1007_s12254_022_00856_z crossref_primary_10_3390_cancers14030626 crossref_primary_10_1080_17474086_2024_2372325 crossref_primary_10_1186_s40164_022_00323_9 crossref_primary_10_1007_s10555_024_10231_5 crossref_primary_10_3389_fphar_2025_1553331 crossref_primary_10_1053_j_seminoncol_2023_05_001 crossref_primary_10_3390_jpm12020197 crossref_primary_10_1016_j_clml_2023_06_006 crossref_primary_10_1080_10428194_2023_2298273 crossref_primary_10_1080_17474086_2023_2276212 crossref_primary_10_1016_j_clml_2022_06_004 crossref_primary_10_1182_blood_2022019386 crossref_primary_10_1186_s12964_022_00854_y crossref_primary_10_1186_s40164_022_00360_4 crossref_primary_10_1002_cam4_6268 crossref_primary_10_1002_cnr2_1432 crossref_primary_10_1111_joim_13395 crossref_primary_10_3390_biomedicines13020252 crossref_primary_10_51643_22562915_408 crossref_primary_10_3390_cancers16244181 crossref_primary_10_3390_cancers16020238 crossref_primary_10_1200_JCO_21_01552 crossref_primary_10_3389_fonc_2023_1288172 crossref_primary_10_1016_j_exphem_2024_104694 crossref_primary_10_3390_jcm12051928 crossref_primary_10_1038_s41392_023_01521_5 crossref_primary_10_33393_grhta_2024_3167 crossref_primary_10_3389_fphar_2022_883655 crossref_primary_10_3390_biomedicines10071587 crossref_primary_10_1007_s40265_024_02111_7 crossref_primary_10_3389_fphar_2021_599561 crossref_primary_10_1016_j_jncc_2023_11_001 crossref_primary_10_1182_bloodadvances_2023010334 crossref_primary_10_3390_biomedicines10112917 crossref_primary_10_3390_jcm11216574 crossref_primary_10_1007_s00277_022_05054_9 crossref_primary_10_1186_s40164_023_00432_z crossref_primary_10_1111_bjh_18841 crossref_primary_10_1080_1120009X_2021_1976912 crossref_primary_10_1016_j_jtct_2025_02_022 crossref_primary_10_1038_s41392_023_01600_7 crossref_primary_10_3390_cancers14174086 crossref_primary_10_6004_jnccn_2022_0021 crossref_primary_10_1182_blood_2022019536 crossref_primary_10_3390_hemato5020016 crossref_primary_10_1002_ajh_26717 crossref_primary_10_1001_jamanetworkopen_2024_14425 crossref_primary_10_1080_17474086_2022_2061947 crossref_primary_10_3389_fphar_2023_1093194 crossref_primary_10_1097_RLU_0000000000005070 crossref_primary_10_1093_ckj_sfad292 crossref_primary_10_3390_cancers14235846 crossref_primary_10_1097_CCO_0000000000001071 crossref_primary_10_3390_cancers15051437 crossref_primary_10_1007_s10637_022_01300_z crossref_primary_10_1097_BS9_0000000000000149 crossref_primary_10_3389_fonc_2023_1067289 crossref_primary_10_3389_fimmu_2024_1360275 crossref_primary_10_3389_fonc_2023_1203470 crossref_primary_10_1016_j_clml_2024_03_011 crossref_primary_10_1016_j_critrevonc_2023_103923 crossref_primary_10_3390_cancers16162816 crossref_primary_10_1002_ajh_27470 crossref_primary_10_1080_16078454_2025_2466261 crossref_primary_10_3390_cancers14071738 crossref_primary_10_3389_fonc_2023_1168622 crossref_primary_10_3390_cancers13163952 crossref_primary_10_1182_bloodadvances_2022008258 crossref_primary_10_3390_biomedicines11061720 crossref_primary_10_1007_s00761_022_01186_9 crossref_primary_10_1016_j_adro_2024_101450 crossref_primary_10_1002_cam4_6563 crossref_primary_10_7759_cureus_41660 crossref_primary_10_3389_fonc_2024_1397053 crossref_primary_10_1002_ajh_26827 crossref_primary_10_3389_fonc_2024_1420920 crossref_primary_10_1177_11795549241298541 crossref_primary_10_1056_NEJMoa2405888 crossref_primary_10_1155_2024_7612622 crossref_primary_10_7759_cureus_46032 crossref_primary_10_3390_ijms232314589 crossref_primary_10_1016_S1470_2045_21_00251_5 crossref_primary_10_3389_fimmu_2022_862084 crossref_primary_10_1002_cam4_5765 crossref_primary_10_1080_10428194_2021_2024819 crossref_primary_10_2217_imt_2023_0307 crossref_primary_10_1016_j_annonc_2024_06_003 crossref_primary_10_1053_j_seminhematol_2023_06_005 crossref_primary_10_12998_wjcc_v11_i7_1458 crossref_primary_10_1016_S1470_2045_21_00138_8 crossref_primary_10_3324_haematol_2021_280284 crossref_primary_10_1007_s11912_022_01292_2 crossref_primary_10_1177_15330338211036526 |
| Cites_doi | 10.1182/blood-2019-127280 10.3324/haematol.2009.019943 10.1200/JCO.2017.76.0793 10.1111/ejh.12973 10.1056/NEJMoa1002965 10.1200/JCO.2011.38.0410 10.3324/haematol.2011.047670 10.1146/annurev.immunol.26.021607.090331 10.1053/j.seminoncol.2010.09.005 10.1038/nature09754 10.1200/JCO.2016.67.3467 10.1016/S0140-6736(15)60165-9 10.1097/00000421-198212000-00014 10.1182/blood-2016-02-699850 10.1182/blood-2018-07-861641 10.1200/JCO.2006.09.2403 10.1158/1078-0432.CCR-11-1942 10.1016/S1470-2045(16)30167-X 10.1182/bloodadvances.2019000984 10.1200/JCO.2007.15.5507 10.3109/10428194.2013.798868 10.1080/19466315.2013.807748 10.1056/NEJMoa1708984 10.1200/JCO.2016.72.1316 10.1182/blood.2019000324 |
| ContentType | Journal Article |
| Copyright | 2021 Elsevier Ltd Elsevier Ltd Copyright © 2021 Elsevier Ltd. All rights reserved. 2021. Elsevier Ltd |
| Copyright_xml | – notice: 2021 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2021 Elsevier Ltd. All rights reserved. – notice: 2021. Elsevier Ltd |
| CorporateAuthor | KEYNOTE-204 investigators |
| CorporateAuthor_xml | – sequence: 0 name: KEYNOTE-204 investigators – name: KEYNOTE-204 investigators |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 0TZ 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1016/S1470-2045(21)00005-X |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Pharma and Biotech Premium PRO ProQuest Central (Corporate) ProQuest Nursing & Allied Health Database (NC LIVE) Oncogenes and Growth Factors Abstracts ProQuest Health & Medical Collection (NC LIVE) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Pharma and Biotech Premium PRO Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Pharma and Biotech Premium PRO MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | 524 |
| ExternalDocumentID | 33721562 10_1016_S1470_2045_21_00005_X S147020452100005X 1_s2_0_S147020452100005X |
| Genre | Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation | Merck Sharp & Dohme Corp (a subsidiary of Merck & Co, Inc, Kenilworth, NJ, USA). |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 0TZ 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c417t-c14aeaf13cd2b32f808cc04d962da799b1b9bd2ddd1bb33f8ec2ffbbf304e0003 |
| IEDL.DBID | 7X7 |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Fri Jul 11 05:45:51 EDT 2025 Fri Jul 25 03:54:11 EDT 2025 Mon Jul 21 05:48:39 EDT 2025 Tue Jul 01 01:53:25 EDT 2025 Thu Apr 24 23:07:47 EDT 2025 Sat Dec 14 16:15:14 EST 2024 Tue Feb 25 20:02:54 EST 2025 Tue Aug 26 16:33:31 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | Copyright © 2021 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c417t-c14aeaf13cd2b32f808cc04d962da799b1b9bd2ddd1bb33f8ec2ffbbf304e0003 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| PMID | 33721562 |
| PQID | 2506714706 |
| PQPubID | 46089 |
| PageCount | 13 |
| ParticipantIDs | proquest_miscellaneous_2501849843 proquest_journals_2506714706 pubmed_primary_33721562 crossref_primary_10_1016_S1470_2045_21_00005_X crossref_citationtrail_10_1016_S1470_2045_21_00005_X elsevier_sciencedirect_doi_10_1016_S1470_2045_21_00005_X elsevier_clinicalkeyesjournals_1_s2_0_S147020452100005X elsevier_clinicalkey_doi_10_1016_S1470_2045_21_00005_X |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-04-01 |
| PublicationDateYYYYMMDD | 2021-04-01 |
| PublicationDate_xml | – month: 04 year: 2021 text: 2021-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2021 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – sequence: 0 name: Elsevier Ltd – name: Elsevier Ltd – name: Elsevier Limited |
| References | Keir, Butte, Freeman, Sharpe (bib11) 2008; 26 Zinzani, Lee, Armand (bib18) 2019; 134 Maurer, Bretz (bib26) 2013; 5 Villa, Seshadri, Puig (bib6) 2012; 97 (bib8) 2019 Goodman, Riedel, Serrano, Gulati, Moskowitz, Yahalom (bib2) 2008; 26 Younes, Bartlett, Leonard (bib27) 2010; 363 Arai, Fanale, DeVos (bib3) 2013; 54 Connors, Jurczak, Straus (bib10) 2018; 378 (bib16) 2020 (bib17) August, 2020 Chen, Gopal, Smith (bib28) 2016; 128 Brockelmann, Zagadailov, Corman (bib31) 2017; 99 Oken, Creech, Tormey (bib24) 1982; 5 Armand, Engert, Younes (bib19) 2018; 132 Zinzani, Chen, Armand (bib23) 2020 Santoro, Mazza, Pulsoni (bib4) 2020; 4 Green, Rodig, Juszczynski (bib14) 2012; 18 Steidl, Shah, Woolcock (bib13) 2011; 471 Weber (bib12) 2010; 37 Chen, Zinzani, Fanale (bib21) 2017; 35 Chen, Zinzani, Lee (bib22) 2019; 134 Armand, Shipp, Ribrag (bib20) 2016; 34 Moskowitz, Walewski, Nademanee (bib9) 2018; 132 Cheson, Pfistner, Juweid (bib25) 2007; 25 Puig, Pintilie, Seshadri (bib5) 2010; 95 Moskowitz, Nademanee, Masszi (bib32) 2015; 385 Younes, Santoro, Shipp (bib29) 2016; 17 Fermé, Mounier, Divine (bib1) 2002; 20 Younes, Gopal, Smith (bib7) 2012; 30 Armand, Engert, Younes (bib30) 2018; 36 (bib15) 2020 Armand (10.1016/S1470-2045(21)00005-X_bib19) 2018; 132 Younes (10.1016/S1470-2045(21)00005-X_bib27) 2010; 363 Goodman (10.1016/S1470-2045(21)00005-X_bib2) 2008; 26 Santoro (10.1016/S1470-2045(21)00005-X_bib4) 2020; 4 (10.1016/S1470-2045(21)00005-X_bib16) 2020 Younes (10.1016/S1470-2045(21)00005-X_bib29) 2016; 17 Chen (10.1016/S1470-2045(21)00005-X_bib22) 2019; 134 Zinzani (10.1016/S1470-2045(21)00005-X_bib18) 2019; 134 (10.1016/S1470-2045(21)00005-X_bib17) 2020 Steidl (10.1016/S1470-2045(21)00005-X_bib13) 2011; 471 Younes (10.1016/S1470-2045(21)00005-X_bib7) 2012; 30 Armand (10.1016/S1470-2045(21)00005-X_bib20) 2016; 34 Green (10.1016/S1470-2045(21)00005-X_bib14) 2012; 18 Moskowitz (10.1016/S1470-2045(21)00005-X_bib9) 2018; 132 (10.1016/S1470-2045(21)00005-X_bib15) 2020 Chen (10.1016/S1470-2045(21)00005-X_bib28) 2016; 128 Puig (10.1016/S1470-2045(21)00005-X_bib5) 2010; 95 Zinzani (10.1016/S1470-2045(21)00005-X_bib23) 2020 Villa (10.1016/S1470-2045(21)00005-X_bib6) 2012; 97 Armand (10.1016/S1470-2045(21)00005-X_bib30) 2018; 36 Arai (10.1016/S1470-2045(21)00005-X_bib3) 2013; 54 Keir (10.1016/S1470-2045(21)00005-X_bib11) 2008; 26 Weber (10.1016/S1470-2045(21)00005-X_bib12) 2010; 37 Brockelmann (10.1016/S1470-2045(21)00005-X_bib31) 2017; 99 (10.1016/S1470-2045(21)00005-X_bib8) 2019 Chen (10.1016/S1470-2045(21)00005-X_bib21) 2017; 35 Cheson (10.1016/S1470-2045(21)00005-X_bib25) 2007; 25 Fermé (10.1016/S1470-2045(21)00005-X_bib1) 2002; 20 Connors (10.1016/S1470-2045(21)00005-X_bib10) 2018; 378 Maurer (10.1016/S1470-2045(21)00005-X_bib26) 2013; 5 Moskowitz (10.1016/S1470-2045(21)00005-X_bib32) 2015; 385 Oken (10.1016/S1470-2045(21)00005-X_bib24) 1982; 5 33794200 - Lancet Oncol. 2021 Apr;22(4):417-419 33932383 - Lancet Oncol. 2021 May;22(5):e184 |
| References_xml | – volume: 17 start-page: 1283 year: 2016 end-page: 1294 ident: bib29 article-title: Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study publication-title: Lancet Oncol – volume: 18 start-page: 1611 year: 2012 end-page: 1618 ident: bib14 article-title: Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy publication-title: Clin Cancer Res – volume: 36 start-page: 1428 year: 2018 end-page: 1439 ident: bib30 article-title: Nivolumab for relapsed/refractory classic Hodgkin Lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial publication-title: J Clin Oncol – volume: 26 start-page: 677 year: 2008 end-page: 704 ident: bib11 article-title: PD-1 and its ligands in tolerance and immunity publication-title: Annu Rev Immunol – volume: 97 start-page: 751 year: 2012 end-page: 757 ident: bib6 article-title: Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy publication-title: Haematologica – volume: 25 start-page: 579 year: 2007 end-page: 586 ident: bib25 article-title: Revised response criteria for malignant lymphoma publication-title: J Clin Oncol – start-page: 1 year: 2020 end-page: 5 ident: bib23 article-title: Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem-cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis publication-title: Leuk Lymphoma – volume: 35 start-page: 2125 year: 2017 end-page: 2132 ident: bib21 article-title: Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma publication-title: J Clin Oncol – volume: 5 start-page: 649 year: 1982 end-page: 655 ident: bib24 article-title: Toxicity and response criteria of the Eastern Cooperative Oncology Group publication-title: Am J Clin Oncol – volume: 37 start-page: 430 year: 2010 end-page: 439 ident: bib12 article-title: Immune checkpoint proteins: a new therapeutic paradigm for cancer—preclinical background: CTLA-4 and PD-1 blockade publication-title: Semin Oncol – year: 2020 ident: bib16 article-title: OPDIVO (nivolumab) injection, for intravenous use [prescribing information] – volume: 132 start-page: 2639 year: 2018 end-page: 2642 ident: bib9 article-title: Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse publication-title: Blood – volume: 30 start-page: 2183 year: 2012 end-page: 2189 ident: bib7 article-title: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma publication-title: J Clin Oncol – volume: 54 start-page: 2531 year: 2013 end-page: 2533 ident: bib3 article-title: Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant publication-title: Leuk Lymphoma – volume: 26 start-page: 5240 year: 2008 end-page: 5247 ident: bib2 article-title: Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma publication-title: J Clin Oncol – year: 2019 ident: bib8 article-title: ADCETRIS (brentuximab vedotin) for injection, for intravenous use [prescribing information] – volume: 128 start-page: 1562 year: 2016 end-page: 1566 ident: bib28 article-title: Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma publication-title: Blood – volume: 34 start-page: 3733 year: 2016 end-page: 3739 ident: bib20 article-title: Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure publication-title: J Clin Oncol – year: August, 2020 ident: bib17 article-title: KEYTRUDA (pembrolizumab) 50 mg powder for concentrate for solution for infusion (summary of product characteristics) – volume: 132 year: 2018 ident: bib19 article-title: Nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous hematopoietic cell transplantation (auto-HCT): extended follow-up of the phase 2 single-arm CheckMate 205 study publication-title: Blood – volume: 95 start-page: 1496 year: 2010 end-page: 1502 ident: bib5 article-title: Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma publication-title: Haematologica – year: 2020 ident: bib15 article-title: KEYTRUDA (pembrolizumab) for injection, for intravenous use – volume: 378 start-page: 331 year: 2018 end-page: 344 ident: bib10 article-title: Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma publication-title: N Engl J Med – volume: 4 start-page: 136 year: 2020 end-page: 140 ident: bib4 article-title: Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma publication-title: Blood Adv – volume: 471 start-page: 377 year: 2011 end-page: 381 ident: bib13 article-title: MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers publication-title: Nature – volume: 363 start-page: 1812 year: 2010 end-page: 1821 ident: bib27 article-title: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas publication-title: N Engl J Med – volume: 385 start-page: 1853 year: 2015 end-page: 1862 ident: bib32 article-title: Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet – volume: 5 start-page: 311 year: 2013 end-page: 320 ident: bib26 article-title: Multiple testing in group sequential trials using graphical approaches publication-title: Stat Biopharm Res – volume: 134 start-page: 240 year: 2019 ident: bib18 article-title: Three-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed/refractory classic Hodgkin lymphoma publication-title: Blood – volume: 20 start-page: 467 year: 2002 end-page: 475 ident: bib1 article-title: Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial publication-title: J Clin Oncol – volume: 134 start-page: 1144 year: 2019 end-page: 1153 ident: bib22 article-title: Pembrolizumab in relapsed or refractory Hodgkin lymphoma: two-year follow-up of KEYNOTE-087 publication-title: Blood – volume: 99 start-page: 553 year: 2017 end-page: 558 ident: bib31 article-title: Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are ineligible for autologous stem cell transplant: a Germany and United Kingdom retrospective study publication-title: Eur J Haematol – volume: 134 start-page: 240 issue: suppl 1 year: 2019 ident: 10.1016/S1470-2045(21)00005-X_bib18 article-title: Three-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed/refractory classic Hodgkin lymphoma publication-title: Blood doi: 10.1182/blood-2019-127280 – volume: 95 start-page: 1496 year: 2010 ident: 10.1016/S1470-2045(21)00005-X_bib5 article-title: Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma publication-title: Haematologica doi: 10.3324/haematol.2009.019943 – volume: 36 start-page: 1428 year: 2018 ident: 10.1016/S1470-2045(21)00005-X_bib30 article-title: Nivolumab for relapsed/refractory classic Hodgkin Lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial publication-title: J Clin Oncol doi: 10.1200/JCO.2017.76.0793 – volume: 99 start-page: 553 year: 2017 ident: 10.1016/S1470-2045(21)00005-X_bib31 article-title: Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are ineligible for autologous stem cell transplant: a Germany and United Kingdom retrospective study publication-title: Eur J Haematol doi: 10.1111/ejh.12973 – volume: 363 start-page: 1812 year: 2010 ident: 10.1016/S1470-2045(21)00005-X_bib27 article-title: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas publication-title: N Engl J Med doi: 10.1056/NEJMoa1002965 – volume: 30 start-page: 2183 year: 2012 ident: 10.1016/S1470-2045(21)00005-X_bib7 article-title: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.2011.38.0410 – volume: 97 start-page: 751 year: 2012 ident: 10.1016/S1470-2045(21)00005-X_bib6 article-title: Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy publication-title: Haematologica doi: 10.3324/haematol.2011.047670 – volume: 26 start-page: 677 year: 2008 ident: 10.1016/S1470-2045(21)00005-X_bib11 article-title: PD-1 and its ligands in tolerance and immunity publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.26.021607.090331 – volume: 37 start-page: 430 year: 2010 ident: 10.1016/S1470-2045(21)00005-X_bib12 article-title: Immune checkpoint proteins: a new therapeutic paradigm for cancer—preclinical background: CTLA-4 and PD-1 blockade publication-title: Semin Oncol doi: 10.1053/j.seminoncol.2010.09.005 – volume: 471 start-page: 377 year: 2011 ident: 10.1016/S1470-2045(21)00005-X_bib13 article-title: MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers publication-title: Nature doi: 10.1038/nature09754 – start-page: 1 year: 2020 ident: 10.1016/S1470-2045(21)00005-X_bib23 article-title: Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem-cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis publication-title: Leuk Lymphoma – volume: 34 start-page: 3733 year: 2016 ident: 10.1016/S1470-2045(21)00005-X_bib20 article-title: Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure publication-title: J Clin Oncol doi: 10.1200/JCO.2016.67.3467 – volume: 385 start-page: 1853 year: 2015 ident: 10.1016/S1470-2045(21)00005-X_bib32 article-title: Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(15)60165-9 – volume: 5 start-page: 649 year: 1982 ident: 10.1016/S1470-2045(21)00005-X_bib24 article-title: Toxicity and response criteria of the Eastern Cooperative Oncology Group publication-title: Am J Clin Oncol doi: 10.1097/00000421-198212000-00014 – year: 2019 ident: 10.1016/S1470-2045(21)00005-X_bib8 – volume: 128 start-page: 1562 year: 2016 ident: 10.1016/S1470-2045(21)00005-X_bib28 article-title: Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma publication-title: Blood doi: 10.1182/blood-2016-02-699850 – volume: 132 start-page: 2639 year: 2018 ident: 10.1016/S1470-2045(21)00005-X_bib9 article-title: Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse publication-title: Blood doi: 10.1182/blood-2018-07-861641 – year: 2020 ident: 10.1016/S1470-2045(21)00005-X_bib16 – volume: 25 start-page: 579 year: 2007 ident: 10.1016/S1470-2045(21)00005-X_bib25 article-title: Revised response criteria for malignant lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.2403 – volume: 18 start-page: 1611 year: 2012 ident: 10.1016/S1470-2045(21)00005-X_bib14 article-title: Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-1942 – volume: 132 issue: suppl 1 year: 2018 ident: 10.1016/S1470-2045(21)00005-X_bib19 article-title: Nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous hematopoietic cell transplantation (auto-HCT): extended follow-up of the phase 2 single-arm CheckMate 205 study publication-title: Blood – volume: 17 start-page: 1283 year: 2016 ident: 10.1016/S1470-2045(21)00005-X_bib29 article-title: Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30167-X – volume: 4 start-page: 136 year: 2020 ident: 10.1016/S1470-2045(21)00005-X_bib4 article-title: Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma publication-title: Blood Adv doi: 10.1182/bloodadvances.2019000984 – year: 2020 ident: 10.1016/S1470-2045(21)00005-X_bib15 – volume: 26 start-page: 5240 year: 2008 ident: 10.1016/S1470-2045(21)00005-X_bib2 article-title: Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.2007.15.5507 – volume: 54 start-page: 2531 year: 2013 ident: 10.1016/S1470-2045(21)00005-X_bib3 article-title: Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant publication-title: Leuk Lymphoma doi: 10.3109/10428194.2013.798868 – volume: 5 start-page: 311 year: 2013 ident: 10.1016/S1470-2045(21)00005-X_bib26 article-title: Multiple testing in group sequential trials using graphical approaches publication-title: Stat Biopharm Res doi: 10.1080/19466315.2013.807748 – volume: 378 start-page: 331 year: 2018 ident: 10.1016/S1470-2045(21)00005-X_bib10 article-title: Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1708984 – year: 2020 ident: 10.1016/S1470-2045(21)00005-X_bib17 – volume: 35 start-page: 2125 year: 2017 ident: 10.1016/S1470-2045(21)00005-X_bib21 article-title: Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.2016.72.1316 – volume: 134 start-page: 1144 year: 2019 ident: 10.1016/S1470-2045(21)00005-X_bib22 article-title: Pembrolizumab in relapsed or refractory Hodgkin lymphoma: two-year follow-up of KEYNOTE-087 publication-title: Blood doi: 10.1182/blood.2019000324 – volume: 20 start-page: 467 year: 2002 ident: 10.1016/S1470-2045(21)00005-X_bib1 article-title: Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial publication-title: J Clin Oncol – reference: 33932383 - Lancet Oncol. 2021 May;22(5):e184 – reference: 33794200 - Lancet Oncol. 2021 Apr;22(4):417-419 |
| SSID | ssj0017105 |
| Score | 2.66481 |
| Snippet | PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma.... SummaryBackgroundPD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical... Summary Background PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 512 |
| SubjectTerms | Adolescent Adult Adverse events Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Autografts Brentuximab Vedotin - administration & dosage Brentuximab Vedotin - adverse effects Creatinine Dehydrogenases Female Hematology, Oncology, and Palliative Medicine Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic stem cells Hodgkin Disease - drug therapy Hodgkin Disease - pathology Hodgkin's lymphoma Humans Hypothyroidism Immunoconjugates - administration & dosage Immunotherapy Leukocytes (neutrophilic) Lymphoma Male Medical prognosis Middle Aged Monoclonal antibodies Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Neutropenia Patients PD-1 protein Pembrolizumab Peripheral neuropathy Pneumonitis Progression-Free Survival Proportional Hazards Models Statistical analysis Stem cell transplantation Targeted cancer therapy Toxicity Treatment Outcome Young Adult |
| Title | Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S147020452100005X https://www.clinicalkey.es/playcontent/1-s2.0-S147020452100005X https://dx.doi.org/10.1016/S1470-2045(21)00005-X https://www.ncbi.nlm.nih.gov/pubmed/33721562 https://www.proquest.com/docview/2506714706 https://www.proquest.com/docview/2501849843 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9RAEF-0BfFF_Pa0lhV8aOHWZjebL19Ey5VD6Vm0hfNpyX5p8e5yXi5g_cv885zZ5NIXa4UQQpLZkPwm87EzO0PIS2N8hOE9JktnmRQyZ3lSSuZEaovYSe7D8rHjSTo-k--nybSbcKu7tMqNTAyC2lYG58gPQFWnGZdZlL5Z_mDYNQqjq10LjZtkG0uXIVdn097h4lmbwohUDMuuX67gOfjcn9wTfB-ldsKmV-mmq2zPoIOO7pI7nfFI37Zo3yM33OI-uXXchccfkN8nbq6xDc-vZl5qihkXTU01FmBqfp63p8ALPV9Q2HAVy7J2llYrOPar0Hjngho0pxE5Oq7s1-9w4-wCEK_mJd37MPoy-Xg6whfaf01LHAZLPc_hsC1tQitPSxqSFEPWpxtS0IW2AmZydkixVRcDtnOzIV1-A_1JYxrq2z4kZ0ej08Mx61ozMCN5tmaGA7al57GxQsfC51FuTCRtkQpbZkWhuS60FdZarnUc-9wZ4b3WPo6kQz_sEdlaVAv3hNAyAY_NWJ_F3kqrjYZxIpvkXuTWlzYeELkBRZmubjm2z5ipPkENsVSIpRJcBSzVdEBe9WTLtnDHdQTpBnG1WZUKclSBarmOMPsboas7aVArrmqhopYaiUUIqiRAmfeUncHTGjL_89CdDVOq_jmX_8iAvOgvA8QYBCoXrmrCPeDUF7mED_u4Zeb--8RxBhZgKp7-e_Bn5LbAzJ6Qv7RDttarxj0H02ytd8P_B_v8kO-S7XejycmnP9siNgk |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VIgEXxJtAgUUCqZVi6l2vX0gIoZIqJU1AIpXS0-J9QUUShzwE4Udx5ucx41cvlHKplIPleNaOZ2ZnJvPNDCHPtHY-pvc8kVnjCS4SLwkz4VkemTSwgrmifKw_iLpH4t0oHG2QX3UtDMIq6z2x2KhNrvE_8l0w1VHMROxHr2ffPJwahdnVeoRGKRY9u_4OIdvi1cFb4O9zzvc7w72uV00V8LRg8dLTDB4rcyzQhquAu8RPtPaFSSNusjhNFVOpMtwYw5QKApdYzZ1TykHgbzGEgHUvkcsiANXEyvS9BlLC4hIyiU_pYZv304qh3Y_NyW3OdtBKhN7oLFt4lq9b2Lz9G-R65azSN6V03SQbdnqLXOlX6fjb5PcHO1E49ufnapIpigiP1YIqbPi0-nFSnoKo92RK4YNVM7OFNTSfw7GbF4N-1lSj-46SQru5-fwVLhyvQcLySUa3e53jwfthB3_Qzkua4TLYWnoCh2UrFZo7mtECFFmgTG2bgu01OQivNW2Ko8E8EHM7btPZF7DXNKBFP9075OhCmHaXbE7zqb1PaBZChKiNiwNnhFFawTq-CRPHE-MyE7SIqJkiddUnHcd1jGUDiENeSuSl5EwWvJSjFnnRkM3KRiHnEUQ1x2VdBQv7tgRTdh5h_DdCu6h2n4VkcsGlX1IjMS-SOCFQJg1l5WCVjtP_3HSrFkrZ3OdUJ1vkafM1sBiTTtnU5qviGpaINBHwYu-Vwty8H1Ah8Dgj_uDfiz8hV7vD_qE8PBj0HpJrHFFFBXZqi2wu5yv7CNzCpXpc6CIlny5a-f8AJlJy0Q |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEF6VIlW8IG4CBRYJpFaKiXe9PoKEEGoTpYSGSrRSeFq8F1QkcYgTQfhliF_HjK--UMpLJT9Ytmd9zMzOrOebGUKeae18DO95IrXGE1wkXhKmwrM8Mt3ACuaK9LHDUTQ4EW_H4XiD_K5zYRBWWc-JxURtMo3_yDtgqqOYidiPOq6CRRzt91_Pv3nYQQojrXU7jVJEhnb9HZZv-auDfeD1c877veO9gVd1GPC0YPHS0wweMXUs0IargLvET7T2helG3KRxt6uY6irDjTFMqSBwidXcOaVc4AuLywkY9wq5GgdxgjqW7DXwEhaX8El8Yg9Lvp9lD3U-NAd3ONtFixF64_Ps4nl-b2H_-jfI9cpxpW9KSbtJNuzsFtk6rELzt8mvIztV2ALo52qaKopoj1VOFRZ_Wv04LQ_BCvh0RmHDDJp5bg3NFrDvFkXTnzXV6Mqj1NBBZj5_hQsna5C2bJrSnWHv4-j9cQ9faPclTXEYLDM9hd2yrArNHE1pAZAsEKe2TcEOmwwE2Zo2xTZhHoi8nbTp_AvYbhrQorbuHXJyKUy7SzZn2czeJzQNYbWojYsDZ4RRWsE4vgkTxxPjUhO0iKiZInVVMx1bd0xkA45DXkrkpeRMFryU4xZ50ZDNy6IhFxFENcdlnRELc7gEs3YRYfw3QptXM1Eumcy59EtqJOZFQCcEyqShrJyt0on6n5tu10Ipm_uc6WeLPG1OA4sxAJXObLYqrmGJ6CYCPuy9Upib7xMEMXifEX_w78GfkC1Qe_nuYDR8SK5xBBgVMKptsrlcrOwj8BCX6nGhipR8umzd_wOb1XcH |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pembrolizumab+versus+brentuximab+vedotin+in+relapsed+or+refractory+classical+Hodgkin+lymphoma+%28KEYNOTE-204%29%3A+an+interim+analysis+of+a+multicentre%2C+randomised%2C+open-label%2C+phase+3+study&rft.jtitle=The+lancet+oncology&rft.au=Kuruvilla%2C+John&rft.au=Ramchandren%2C+Radhakrishnan&rft.au=Santoro%2C+Armando&rft.au=Paszkiewicz-Kozik%2C+Ewa&rft.date=2021-04-01&rft.eissn=1474-5488&rft.volume=22&rft.issue=4&rft.spage=512&rft_id=info:doi/10.1016%2FS1470-2045%2821%2900005-X&rft_id=info%3Apmid%2F33721562&rft.externalDocID=33721562 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1470-2045&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1470-2045&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1470-2045&client=summon |